Omega-3 fatty acids, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are foundational nutrients for improving insulin sensitivity, reducing systemic inflammation, and supporting patients with metabolic syndrome—clinical patterns commonly seen in both men and women seeking hormone optimization. Beyond their metabolic effects, EPA and DHA provide clinically meaningful cardiovascular support through triglyceride reduction, improvement in endothelial function, and modulation of inflammatory pathways involved in vascular disease. These benefits extend beyond standard lipid panels, contributing to improvements in lipid particle quality and overall cardiometabolic risk.
For BHRT providers, this is particularly relevant because insulin resistance, estrogen deficiency, and androgen imbalance frequently coexist and synergistically accelerate cardiovascular dysfunction. Omega-3 fatty acids function as a metabolic and vascular bridge—supporting glucose regulation, reducing vascular inflammation, and preserving endothelial integrity while hormone therapies address underlying endocrine deficiencies. This complementary mechanism makes EPA/DHA one of the most broadly applicable supplements in hormone-focused care and an appropriate consideration for the majority of patients, especially during Heart Health Month.
Clinical Note (Dosing):
Typical therapeutic dosing for EPA/DHA ranges from 1–4 g daily of combined EPA/DHA, individualized based on triglyceride levels, inflammatory burden, and overall cardiometabolic risk, with higher doses commonly used under clinical supervision.
Safety Considerations:
Omega-3 fatty acids are generally well tolerated; however, caution is advised in patients using anticoagulant or antiplatelet medications, those with known bleeding disorders, or individuals scheduled for surgery. Clinical monitoring and temporary dose adjustment may be appropriate when using higher therapeutic doses.
Key References
- Mozaffarian, D., & Wu, J. H. Y. (2011). Omega-3 fatty acids and cardiovascular disease: Effects on risk factors, molecular pathways, and clinical events. Journal of the American College of Cardiology, 58(20), 2047–2067.
- Bhatt, D. L., et al. (2019). Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine, 380(1), 11–22. Calder, P. C. (2017). Omega-3 fatty acids and inflammatory processes. Nutrients, 9(7), 760.
